Paroxysmal Kinesigenic Dyskinesia and Progressive Ataxia‐Spasticity Syndrome Caused by a Biallelic Variant in KCNJ10 Authors: Clément Desjardins, Jiyoon Baik, Lorenzo Bresciani, Christelle Nilles, Cendrine Foucard, Mathieu Georget, Lina Daghsen, Bertrand Degos, Aurélie Méneret, Emmanuel Roze Published: 2026 Biallelic KCNJ10 variants, encoding the Kir4.1 potassium channel, can cause cerebellar ataxia variably associated with intellectual disability, renal tubulopathy, sensorineural hearing loss and epilepsy (EAST or SeSAME syndrome, MIM:612780). 1 , 2 The predominant movement disorder, cerebellar ataxia, is typically non‐progressive, though dystonic posturing occurs. 3 Genotype–phenotype correlations are poorly known. 1 , 3 Both monoallelic and biallelic KCNJ10 variants can cause paroxysmal kinesigenic dyskinesia (PKD), defined by brief dystonic or choreic attacks triggered by sudden movements, as a predominant manifestation. 4 , 5 , 6 Notably, paroxysmal features resembling PKD were retrospectively identified in one of three previously reported siblings carrying the homozygous p.(Ile60Thr) variant. 6 , 7 We report a patient with biallelic KCNJ10 variant presenting with PKD and progressive ataxia‐spasticity. Case Report A 33‐year‐old woman presented with PKD, progressive ataxia‐spasticity syndrome, and dystonic postures. She had asymptomatic parents with no family history for neurological disorders (Supplementary Fig. S1). Generalized tonic–clonic seizures at 10 months, treated with valproate, remitted after discontinuation at age 2 without recurrence. She exhibited developmental delay with independent ambulation at 30 months, and persistent coordination difficulties. At age 8, PKD episodes appeared, preceded by a sensory aura, with dystonic posturing of the upper limbs and neck, lasting 5–60 seconds, about three times daily. Episodes were typically triggered by sudden movements and positional changes, and favored by fatigue, or laughter. Initial treatment with carbamazepine was discontinued for intolerance (asthenia and dizziness). Oxcarbazepine (600 mg daily) achieved near‐complete episode suppression. Over the years, she developed slowly progressive ataxia‐spasticity with dystonic posturing and bilateral mixed hearing loss documented by audiometry, with otoscopy and tympanometry excluding another cause. Serial examinations documented progressive worsening over 16 years (Videos 1 and 2). At age 17, examination showed mild gait ataxia, ataxic dysarthria, and dystonic hand posturing. At age 33, she had marked gait ataxia (SARA score 13.5/40), mixed ataxic‐spastic dysarthria, saccadic pursuit with hypometric saccades, left‐predominant dysmetria, sustained dystonic postures with finger extension, and lower‐limb spasticity with bilateral Babinski sign. Cognition was preserved on comprehensive neuropsychological assessment. Oxcarbazepine maintained excellent PKD control, whereas the progressive ataxia‐spasticity remained refractory to symptomatic treatment. Serial neurological examination at 17 years (2010) and 33 years (2026) demonstrating progressive cerebellar syndrome. Part I: gait ataxia with marked worsening; Part II: mixed ataxic‐spastic dysarthria; Part III: bilateral dysmetria, predominantly left‐sided (2026 only). Dystonia and pyramidal signs. Part I: dystonic hand posturing with finger extension at age 17 (2010) and 33 years (2026) demonstrating progression; Part II: lower limb spasticity with hyperreflexia and bilateral Babinski signs (2026 only). Brain and spinal cord MRI were normal (Supplementary Fig. S2). Serum and urinary electrolytes and renal function were normal, without tubulopathy. Cerebrospinal fluid (CSF) analysis was normal including lactate and CSF‐to‐blood glucose ratio of 0.69. Targeted gene panel testing (CACNA1A, KCNA1, PRRT2, SLC2A1, ATP1A3, PNKD, ADCY5) was unrevealing. Trio whole‐genome sequencing identified a biallelic KCNJ10 variant NM_002241.5:c.179 T>C;p.(Ile60Thr) with no other pathogenic variant in ataxia and spasticity genes. It is rare in gnomAD (0.00001196, no homozygotes), predicted deleterious in silico and classified as likely pathogenic by ACMG criteria. Both unaffected parents were heterozygous carriers. Discussion Our observation further indicates that PKD is a cardinal manifestation in patients with a biallelic KCNJ10 p.(Ile60Thr) variant. Our patient had typical PKD with a sustained oxcarbazepine response and developed progressive ataxia‐spasticity, documented over 16 years by serial video examinations, contrasting with the typically non‐progressive course of EAST/SeSAME. 3 It is a single observation, and functional consequences of the variant were not assessed. We thus cannot exclude that unidentified modifiers could contribute to the progressive ataxia‐spasticity. Kir4.1 is the principal astrocytic inwardly rectifying potassium channel, where predominantly homomeric channels set the resting membrane potential, by mediating potassium buffering and the clearance of potassium released during neuronal activity. 1 , 2 Although no functional data is available for p.(Ile60Thr), a variant at a nearby residue within the same transmembrane domain, p.(Arg65Pro), experimentally disrupts Kir4.1 function, 8 while PKD‐associated KCNJ10 variants reduce Kir4.1 currents. 4 Loss of astrocytic Kir4.1 function raises extracellular potassium and neuronal excitability, and in the cerebellum produces deep cerebellar nuclei hyperexcitability, a plausible substrate for PKD, 4 that parallels PRRT2‐related dyskinesia. 9 By contrast, in the renal distal convoluted tubule, Kir4.1 functions primarily as a heteromer with Kir5.1. 1 , 2 Tissue‐specific channel assembly might explain the dissociation between the severe neurological phenotype and the absence of tubulopathy in our patient. Patients with biallelic KCNJ10 variants typically have a variable combination of epilepsy, ataxia, sensorineural hearing loss, and renal tubulopathy (Supplementary Table S1). 1 , 2 , 3 KCNJ10‐related PKD has been proposed as distinct from EAST/SeSAME, 4 , 5 , 6 with non‐paroxysmal dystonia reported for a heterozygous variant;10 our case rather supports a phenotypic continuum. Here, a variant associated only with EAST‐like features 7 produced PKD with progressive ataxia‐spasticity, hearing loss, and dystonia, yet without tubulopathy. Unlike PKD‐predominant cases, which show only subtle EAST features, 5 her oculomotor signs occurred within a progressive cerebellar and pyramidal syndrome differing from previously described presentations of this variant. 5 , 7 Normal neuroimaging despite clinical progression supports a channelopathy rather than neurodegeneration. Hearing loss was mixed, combining conductive and sensorineural components, unlike the purely sensorineural pattern of EAST/SeSAME. 1 , 2 This observation indicates that biallelic KCNJ10 variants should be considered a treatable cause of PKD in patients with associated cerebellar ataxia and pyramidal features. Author Roles At the end of the manuscript, list the itemized contributions in number/letter format, as below. These should include but are not restricted to: (1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the first draft, B. Review and Critique. C.D.: 1A, 1B, 1C, 3A. J.B.: 1A, 1C, 3A. L.B.: 1A, 1C, 3A. C.N.: 1B, 1C, 3B. C.F.: 1B, 1C, 3B. M.G.: 1B, 1C, 3B. L.D.: 1B, 1C, 3B. B.D.: 1B, 1C, 3B. A.M.: 1B, 1C, 3B. E.R.: 1A, 1B, 1C, 3B. Disclosures Ethical Compliance Statement: Under French ethics and regulatory law (Code de la Santé Publique), retrospective studies based on usual care data do not require ethics committee approval. The authors confirm that institutional review board approval was not required for this work. The patient provided written informed consent for publication of this case report and accompanying video material. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Financial Disclosures and Conflicts of Interest: This work was funded by a grant from the Fondation Maladies Rares (N° Omics2025‐15,562) and was supported by the Fondation pour la Recherche Médicale (grant number FDM202501050019 to CD). The authors declare that there are no conflicts of interest relevant to this work. CD declares that he has received research grant from Fondation pour la Recherche Médicale (FRM, grant number FDM202501050019); honoraria from HomePerf, ASDIA Parkinson, Ever Pharma, TEVA Santé and Expression Santé; consulting fees from TEVA Santé and travel funding from ELIVIE and Merz pharma; participated in advisory board for Aguettant. Aurélie Méneret received speaker honoraria from Abbvie and Merz‐Pharma. CF received travel funding from Merz Pharma. BD received honorarium for scientific consulting from MERZ and Orion Pharma, and for educational event from IPSEN. ER received honoraria for speeches from Orkyn, Aguettant, Elivie, Merz‐Pharma, Teva, Everpharma; participated in advisory boards for Merz Pharma, Elivie, and Teva; and received research support from Merz‐Pharma, Orkyn, Elivie, Everpharma, and Aguettant. Jiyoon Baik, Lorenzo Bresciani, Christelle Nilles, Lina Daghsen and Mathieu Georget have no disclosures. Author disclosures are available in the Supporting Information. Supporting information Figure S1 Family pedigree. Three‐generation pedigree of a non‐consanguineous family of European ancestry, with a family history negative for neurological disorders. Squares indicate males and circles females. The arrow indicates the proband, homozygous for the KCNJ10 variant NM_002241.5:c.179 T>C p.(Ile60Thr) (filled symbol). Both unaffected parents are heterozygous carriers (central dot). Trio whole‐genome sequencing was performed in the proband and both parents. Figure S2 Serial brain MRI. (A) MRI at 17 years (2010) and (B) at 33 years (2026). For each time point, a sagittal T1‐weighted image (right) shows normal cerebellar trophicity, and an axial T2 FLAIR‐weighted image (left) shows no abnormality. Imaging remained normal despite clinical progression, in particular without cerebellar atrophy. TABLE S1 Clinical and neuroimaging features of patients with biallelic KCNJ10 variants. Abbreviations: n, number of affected cases; DD, developmental delay; ID, intellectual disability; DQ, developmental quotient; NR, not reported; +, present; −, absent; ±, variable or partial; het, heterozygous. †Neurological reassessment of previously reported patients from Scholl et al 2009 and Bockenhauer et al 2009. *Review article, data compiled from previously reported cases Data S1 Supporting Information.